These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 33401953)

  • 1. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
    Abdel-Qadir H; Bobrowski D; Zhou L; Austin PC; Calvillo-Argüelles O; Amir E; Lee DS; Thavendiranathan P
    J Am Heart Assoc; 2021 Jan; 10(2):e018393. PubMed ID: 33401953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study.
    Abdel-Qadir H; Tai F; Croxford R; Austin PC; Amir E; Calvillo-Argüelles O; Ross H; Lee DS; Thavendiranathan P
    Circ Heart Fail; 2021 Jul; 14(7):e008110. PubMed ID: 34187164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study.
    Seicean S; Seicean A; Plana JC; Budd GT; Marwick TH
    J Am Coll Cardiol; 2012 Dec; 60(23):2384-90. PubMed ID: 23141499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
    Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
    J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study.
    Thavendiranathan P; Abdel-Qadir H; Fischer HD; Camacho X; Amir E; Austin PC; Lee DS
    J Clin Oncol; 2016 Jul; 34(19):2239-46. PubMed ID: 27091709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.
    Calvillo-Argüelles O; Abdel-Qadir H; Michalowska M; Billia F; Suntheralingam S; Amir E; Thavendiranathan P
    Can J Cardiol; 2019 Feb; 35(2):153-159. PubMed ID: 30760421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
    Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
    JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis.
    Obasi M; Abovich A; Vo JB; Gao Y; Papatheodorou SI; Nohria A; Asnani A; Partridge AH
    Cancer Causes Control; 2021 Dec; 32(12):1395-1405. PubMed ID: 34406595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of Trastuzumab and Anthracycline-induced Cardiotoxicity Using Angiotensin-converting Enzyme Inhibitors or β-blockers in Older Adults With Breast Cancer.
    Wittayanukorn S; Qian J; Westrick SC; Billor N; Johnson B; Hansen RA
    Am J Clin Oncol; 2018 Sep; 41(9):909-918. PubMed ID: 28537988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
    Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
    J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study.
    Jacobse JN; Schaapveld M; Boekel NB; Hooning MJ; Jager A; Baaijens MHA; Hauptmann M; Russell NS; Rutgers EJT; Aleman BMP; Sonke GS; van Leeuwen FE
    Breast Cancer Res Treat; 2021 Jan; 185(1):205-214. PubMed ID: 32964358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials.
    D'Amario D; Laborante R; Bianchini E; Galli M; Ciliberti G; Mennuni M; Patti G
    Int J Cardiol; 2023 Nov; 391():131219. PubMed ID: 37527752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart failure after treatment for breast cancer.
    Boekel NB; Duane FK; Jacobse JN; Hauptmann M; Schaapveld M; Sonke GS; Gietema JA; Hooning MJ; Seynaeve CM; Maas AHEM; Darby SC; Aleman BMP; Taylor CW; van Leeuwen FE
    Eur J Heart Fail; 2020 Feb; 22(2):366-374. PubMed ID: 31721395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study.
    Abdel-Qadir H; Thavendiranathan P; Austin PC; Lee DS; Amir E; Tu JV; Fung K; Anderson GM
    J Natl Cancer Inst; 2019 Aug; 111(8):854-862. PubMed ID: 30715404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure.
    Seicean S; Seicean A; Alan N; Plana JC; Budd GT; Marwick TH
    Circ Heart Fail; 2013 May; 6(3):420-6. PubMed ID: 23425978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.
    Leung HW; Chan AL
    Expert Opin Drug Saf; 2015; 14(11):1661-71. PubMed ID: 26461271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
    JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
    Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
    Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
    Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
    Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.